Starling Oncology (STLNW) Non Operating Interest Expenses (2021 - 2026)

Starling Oncology (STLNW) has reported Non Operating Interest Expenses for 6 consecutive years, with $1.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses fell 0.59% year-over-year to $1.9 million; the trailing twelve-month figure through Jun 2026 stood at $7.6 million (down 29.58% YoY), and the FY2025 full-year result was $11.3 million, up 50.43% from the prior year.
• Non Operating Interest Expenses eased to $1.9 million in Q2 2026 per STLNW's latest filing, from $1.9 million in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $5.6 million in Q1 2025 and bottomed at $61000.0 in Q2 2022.
• Historically, Non Operating Interest Expenses has averaged $1.9 million across 5 years, with a median of $1.9 million in 2025.
• The sharpest annual moves came in 2023 and 2026: Non Operating Interest Expenses soared 2585.25% in 2023, then plunged 65.28% in 2026.
• Over 5 years, Non Operating Interest Expenses stood at $61000.0 in 2022, then jumped by 3081.97% to $1.9 million in 2023, then sank by 39.82% to $1.2 million in 2024, then jumped by 64.04% to $1.9 million in 2025, then dropped by 2.97% to $1.9 million in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $1.9 million, $1.9 million, and $1.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.